QuantumPharm Showcases AI and Automation-Powered API Development at CPHI Shenzhen 2024
XtalPi
Computation-Driven Innovative Drug R&D Provider
From September 9 to 11, 2024, the second CPHI & PMEC Pharmaceutical Industry Exhibition (Shenzhen) will grandly open at the Shenzhen Futian Exhibition Center. XtalPi (QuantumPharm, stock code:2228.HK) As a pioneer and practitioner in the fields of biomedicine and new materials,Dr. Jian Ma, Co-founder and CEO of XtalPiInvited to participate in the seminar and discuss with several academicians and scholars the current situation of China's API industry, XtalPi's new generation of automation-empowered API research and development and its application cases, experimental design schemes by large models, recommended analytical methods, and other breakthroughs and advancements brought by cutting-edge technologies.
China's API industry plays a key role in the global API sector. The efficiency challenges currently faced by the API industry are mainly divided into four aspects:
The emergence of new therapeutic approaches in the international pharmaceutical market has placed new demands on compounds and posed greater challenges to the supply capacity of active pharmaceutical ingredients (APIs);
The rapid changes in the market environment and intense pipeline competition have led downstream companies to place higher demands on the novelty of compound blocks.
Facing market competition pressure, active pharmaceutical ingredients (APIs) urgently need to enhance the added value of products and the bargaining power in the value chain.
Delivery efficiency and the success rate of finished product synthesis have always been the focus of the industry. Trading businesses face high inventory risks, and the judgment of new demands requires continuous optimization and iteration.
In response to these challenges,Dr. Jian Ma, Co-founder and CEO of XtalPiAs "AI + Automation Empower API R&D"XtalPi Shares Achievements in Empowering API Design and Development with Next-Gen AI and Automated Synthesis Technologies, Including Intelligent Software, Automated Workstations, and Standardized Data to Drive Innovation in the Field of Chemistry;"By leveraging the characteristics of artificial intelligence in drug discovery to generate data, we can combine algorithms with professional expertise, from establishing algorithm frameworks to achieving laboratory automation, thereby continuously accumulating experience and making improvements throughout the research and development process.
By integrating computing power, algorithms, and data generation, XtalPi's AI model has demonstrated exceptional reaction success rates, including amide condensation reactions, Suzuki coupling reactions, and reductive amination reactions. With richer reaction data and shorter data acquisition times, it holds an advantage in traditional library synthesis operations.
Dr. Ma Jian provided a detailed introduction to XtalPi's innovative end-to-end library design and automated synthesis process.：From ID4IdeaTM And ID4GibbsTM The design of new molecules begins, through AI-driven reaction design, combined with AI-powered raw material preparation, precise reaction operations by automated robots, to automated reaction analysis and post-processing, and finally completing compound management via intelligent separation and purification as well as automated workstations. The entire process runs smoothly on a fully digitized platform, aiming to expand the boundaries of chemical research and enhance the speed and quality of analysis.
Looking ahead, with the automation and intelligence of data processing and collection, and the enhancement of AI's deep learning capabilities based on big data models, XtalPi will be able to predict reaction conditions and synthetic feasibility more accurately, driving the development of new quality productive forces.
